Skip to main content
The NCI Community Hub will be retiring in May 2024. For more information please visit the NCIHub Retirement Page:https://ncihub.cancer.gov/groups/ncihubshutdown/overview
close

NCL Method STE-3

By Timothy Potter, Barry Neun, Anna Ilinskaya1, Marina Dobrovolskaia

Leidos Biomedical Research, Inc.

Detection of Mycoplasma

Listed in Datasets | publication by group NCL Protocols

Version 3.0 - published on 26 May 2020 doi:10.17917/R1XZ-X580 - cite this

Licensed under these terms

Description

Mycoplasma is a form of bacteria that lacks a nucleus and a cell wall, and are thus unaffected by many antibiotics. Nanoparticles submitted to the NCL may be subjected to testing for mycoplasma when deemed necessary. The types of nanoparticle formulations generally tested for mycoplasma contamination include those that incorporate a component derived from an animal or hybridoma cultures.

Content List

Cite this work

Researchers should cite this work as follows:

Relation to series

The publication is part of the series below:

Recommendations

Powered by ...

NCL Protocols

NCL Protocols group image

When watching a publication, you will be notified when a new version is released.